Utthara Nayar, Ph.D.
Affiliations: | 2011 | Weill Cornell Medical College, New York, NY, United States |
Area:
Cell Biology, Virology BiologyGoogle:
"Utthara Nayar"Parents
Sign in to add mentor| Ethel Cesarman | grad student | 2011 | Weill Cornell Medical College | |
| (Identification of novel cellular and viral inhibitors in gammaherpesvirus-associated malignancies.) | ||||
| Nikhil Wagle | post-doc | 2015-2020 | Harvard Medical School, Dana Farber Cancer Institute, Broad Institute of Harvard and MIT, | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Brett JO, Dubash TD, Johnson GN, et al. (2023) A Gene Panel Associated With Abemaciclib Utility in -Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression. Jco Precision Oncology. 7: e2200532 |
| Qi M, Nayar U, Ludwig LS, et al. (2021) cDNA-detector: detection and removal of cDNA contamination in DNA sequencing libraries. Bmc Bioinformatics. 22: 611 |
| Mao P, Cohen O, Kowalski KJ, et al. (2020) Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Wander SA, Cohen O, Gong X, et al. (2020) The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. Cancer Discovery |
| Persky NS, Hernandez D, Do Carmo M, et al. (2020) Defining the landscape of ATP-competitive inhibitor resistance residues in protein kinases. Nature Structural & Molecular Biology. 27: 92-104 |
| Nayar U, Cohen O, Kapstad C, et al. (2018) Acquired HER2 mutations in ER metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nature Genetics |
| Wander SA, Cohen O, Johnson GN, et al. (2018) Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i). Journal of Clinical Oncology. 36: 12016-12016 |
| Nayar U, Sadek J, Reichel J, et al. (2017) Identification of a nucleoside analog active against adenosine kinase-expressing plasma cell malignancies. The Journal of Clinical Investigation |
| Nayar U, Sadek J, Reichel JB, et al. (2015) Exquisite Sensitivity of Plasma Cell Malignancies to a Novel Nucleoside Analog Is Mediated By Overexpressed Adenosine Kinase Blood. 126: 1812-1812 |
| Nayar U, Reichel J, Sadek J, et al. (2015) Abstract 4496: Genomics-based resistome analysis revealed endogenous adenosine kinase levels as a chief determinant of specificity for a novel nucleoside analog lymphoma inhibitor Cancer Research. 75: 4496-4496 |